- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Relay Therapeutics Inc (RLAY)
Relay Therapeutics Inc stock price live, this page displays NASDAQ RLAY stock exchange data. View the RLAY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Relay Therapeutics Inc real time stock price chart below.
What Is the Relay Therapeutics Inc Stock Price Today?
The Relay Therapeutics Inc stock price today is 6.50.
What Is the Stock Symbol for Relay Therapeutics Inc?
The stock symbol for Relay Therapeutics Inc is ""RLAY.""
What Stock Exchange Does Relay Therapeutics Inc Trade On?
Relay Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Relay Therapeutics Inc a Good Stock to Buy?
Determining whether Relay Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RLAY quote. (ISIN: US75943R1023)
What Is the Relay Therapeutics Inc Stock Price Today?
The Relay Therapeutics Inc stock price today is 6.50.
What Is the Stock Symbol for Relay Therapeutics Inc?
The stock symbol for Relay Therapeutics Inc is ""RLAY.""
What Stock Exchange Does Relay Therapeutics Inc Trade On?
Relay Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Relay Therapeutics Inc a Good Stock to Buy?
Determining whether Relay Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RLAY quote. (ISIN: US75943R1023)
NASDAQ
Currency in USD
Fair Value
An estimate of a Relay's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.21
7.00
52 wk Range
1.78
7.07
RLAY Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
RLAY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Relay's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.217.00
52 wk Range
1.787.07
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RLAY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Relay's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
13.60
Upside
+109.23%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Relay Therapeutics Inc Company Profile
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Relay Therapeutics Inc SWOT Analysis
AI-Driven Innovation | Explore Relay Therapeutics' pioneering AI platform for decoding protein behavior, revolutionizing drug discovery and development in oncology |
Clinical Progress | Delve into the promising Phase 3 ReDiscover-2 trial of RLY-2608, a potential game-changer in PIK3CA-mutated breast cancer treatment |
Financial Resilience | Learn about Relay's strong cash position extending operations into 2029, enabling focused development despite market challenges |
Market Valuation | Analyst price targets range from $12 to $17, reflecting optimism in Relay's potential despite competitive pressures in the PI3Ka inhibitor space |
Compare RLAY to Peers and Sector
Metrics to compare | RLAY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRLAYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.6x | −4.9x | −0.7x | |
PEG Ratio | −0.15 | 0.09 | 0.00 | |
Price/Book | 1.7x | 0.7x | 2.6x | |
Price / LTM Sales | 134.1x | 26.2x | 3.4x | |
Upside (Analyst Target) | 123.1% | 221.4% | 38.0% | |
Fair Value Upside | Unlock | 12.4% | 5.3% | Unlock |
Analyst Ratings
10 Buy
2 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 13.60
(+109.23% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-0.41 / -0.49
Revenue / Forecast
700.00K / 66.67K
People Also Watch
FAQ
What Stock Exchange Does Relay Trade On?
Relay is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Relay?
The stock symbol for Relay is "RLAY."
What Is the Relay Market Cap?
As of today, Relay market cap is 1.12B.
What Is Relay's Earnings Per Share (TTM)?
The Relay EPS (TTM) is -1.92.
When Is the Next Relay Earnings Date?
Relay will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is RLAY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Relay Stock Split?
Relay has split 0 times.
How Many Employees Does Relay Have?
Relay has 197 employees.
What is the current trading status of Relay (RLAY)?
As of 11 Oct 2025, Relay (RLAY) is trading at a price of 6.50, with a previous close of 6.78. The stock has fluctuated within a day range of 6.21 to 7.00, while its 52-week range spans from 1.78 to 7.07.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.